2017 American Transplant Congress
Comparison Between IgG, C1q and C3d Single Antigen Bead Assays in Detecting Class I Complement-Binding Anti-HLA Antibodies.
Introduction. Donor specific antibodies (DSA) are associated with an increased risk of chronic antibody mediated rejection (CAMR). DSA characterization by single antigen bead (SAB) assays…2017 American Transplant Congress
IVIG + Rituximab as Desensitization Agents to Reduce Donor Specific Antibodies and Improve Transplant Rates in Highly Hla Sensitized (HS) Awaiting Deceased Donor Kidney Transplantation.
Medicine, Cedars-Sinai Medical Center, Los Angeles, CA
Background: HS patients are at risk for development of donor specific antibodies (DSA) and the persistence of DSA is associated with poor graft outcomes. Rituximab,…2017 American Transplant Congress
Antibody Mediated Rejection and Donor Specific Antibodies in Heart Transplant Patients: Single Center Experience.
BACKGROUND AND AIMS: Preexisting donor specific antibodies (DSA) cause acute antibody mediated rejection (AMR), which can be avoided during pre-transplant work up. Diagnosis and management…2017 American Transplant Congress
Circulating Donor-Specific Anti-HLA Antibodies Accelerate the Progression of Interstitial Fibrosis in Kidney Allografts.
Paris Translational Research Center for Organ Transplantation, Paris, France
Interstitial fibrosis represents a major cause of kidney allograft failure. Addressing the causes of accelerated ageing of kidney allografts represents an important challenge to improve…2017 American Transplant Congress
C3d-Binding Anti-DQ DSA Is Associated with a High Risk for Late ABMR and Graft Failure in Stable Kidney Transplant Recipients.
Introduction:Donor specific anti-HLA antibodies (DSA) are a major cause of antibody-mediated rejection (ABMR) and poor graft outcome in kidney transplant recipients (KTR). Critical issue is…2017 American Transplant Congress
Tocilizmab (Anti-IL-6R) Treatment (TCZ-Rx) Reduced Total IgG Levels Including Anti-HLA IgG: Analysis of IgG Subclasses (IgG1-IgG4) and Anti-HLA IgG Subclasses Show Similar Reductions in All Subclasses from Patients with DSA+ Chronic Antibody-Mediated Rejection (CABMR).
Background: DSA+ CABMR constitutes the major cause for renal allograft loss in the U.S. Currently there are no approved therapies. We have reported TCZ use…2017 American Transplant Congress
Refinement of an Old Faithful: A Standardized Flow Cytometry Approach to Measure Donor-Recipient Alloreactivity (a Pilot Study).
Purpose: Donor-specific antibody (DSA) and antibody (Ab)-mediated rejection are challenges in long-term outcomes and limit re-transplantation. Sensitizing events such as homografts in surgical procedures, assist…2017 American Transplant Congress
Lower Mean Tacrolimus Troughs Increase Risk of De Novo Donor-Specific Antibodies in the First Year of Kidney Transplant.
University of Colorado, Aurora, CO
Development of de novo donor-specific antibodies (dnDSA) is the first step in the evolution of antibody-mediated rejection, which constitutes the leading cause of death-censored graft…2017 American Transplant Congress
Complement Activating Anti-HLA Antibodies: Identification of Specific Histo-Mmolecular Phenotype of Rejection for Complement-Targeting Therapy.
Addressing the heterogeneity of antibody-mediated allograft rejection by identifying phenotypes based on pathophysiology is critical for improving outcomes in transplantation. We investigated whether complement-binding anti-HLA…2017 American Transplant Congress
Blood Transfusion Before Organ Transplant: Patient Sensitization and Outcomes.
Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN
BackgroundBlood transfusions (Btf) can cause alloimmunization to HLA antigens. Antibodies to HLA (HLAb) can increase patients' calculated panel reactive assay (cPRA) and make it more…
- « Previous Page
- 1
- …
- 25
- 26
- 27
- 28
- 29
- …
- 47
- Next Page »